Abstract:Background Although staphylokianse (SAK) is among the most promising blood dissolving agents, it is far from ideal. It is interesting to hypothesize that the clot lysis efficacy of SAK can be enhanced with direct active platelet binding ability, and at the same time the rethrombosis complication after successful recanalization can be minimized with an antiplatelet aggregation activity. The present study was performed to characterize the functional properties of RGD-SAK, a novel mutant of staphylokinase (SAK). Results By using site-directed mutagenesis, an Arg-Gly-Asp (RGD) motif was engineered in the staphylokinase (SAK). This mutant of SAK designated RGD-SAK was expressed, purified and characterized. Biochemical analysis indicated that RGD-SAK maintained the similar structure and the fibrinolytic function of SAK. Measurement of platelet binding activity in vitro demonstrated that RGD-SAK had a much higher affinity with platelets than SAK. In vitro platelet-rich clot lysis assay demonstrated that the engineered mutant outperformed the non-manipulated SAK. The time required for 50% platelet-rich clot lysis and the concentration required to obtain 50% clot lysis (C 50 ) were reduced significantly across different concentrations of RGD-SAK comparing with SAK. Meanwhile, RGD-SAK was found to inhibit ADP-induced platelet aggregation in a concentration-dependent manner while SAK had negligible effect on platelet aggregation. Conclusion RGD-SAK possessed the bifunction to target platelet-rich clots and to block platelets aggregation, and thus may serve as a more potential thrombolytic agent with platelet-targeted thrombolytic and antiplatelet aggregation activities in compared with SAK.

Inhibition of Platelet Aggregation of A Mutant Proinsulin Molecule Engineered by Introduction of A Native Arg-Gly-Asp Sequence

Platelet aggregation inhibitory activity of mutant proinsulin with C-peptide replaced by CRGDSC sequence

Gene Construction, Expression, Purification and Activity Analysis of Anti-platelet Aggregation Peptide RGD226

Effect of disulfide bond on the conformation and anticoagulant activity of an Arg-Gly-Asp motif displayed on a mutant insulin protein framework

Monitoring and Inhibition of Insulin Fibrillation by a Small Organic Fluorogen with Aggregation-Induced Emission Characteristics.

(A6,A11)-MUTANT PROINSULIN AS A SCAFFOLD FOR PRESENTING EXOGENOUS FUNCTIONAL-MOTIFS

Study on preparation and unique properties of a novel insulin analogue with N-terminal Arg-4, Pro-3, Lys-2, Pro-1extension at insulin B-chain

Intra-A Chain Disulfide Bond (A6-11) of Insulin is Essential for Displaying Its Activity

Clues to the Design of Aggregation-Resistant Insulin from Proline Scanning of Highly Amyloidogenic Peptides Derived from the N-Terminal Segment of the A-Chain

Effects of Deletion and Shift of the A20-B19 Disulfide Bond on the Structure, Activity, and Refolding of Proinsulin.

Role of Proinsulin Self-Association in Mutant INS Gene-Induced Diabetes of Youth

CONSTRUCTION AND EXPRESSION OF INTRA-A CHAIN DISULFIDE BOND SHIFT MUTANT IN HUMAN PROINSULIN GENE

A Study on the Expression of Site-Directed Mutated Human Proinsulin Gene in Non-Β Cell Lines

Efficient Encapsulation of Insulin by Giant Macrocycle as a Powerful Approach to the Inhibition of Its Fibrillation

A New Method for Preparation of Monomeric Destetrapeptide Human Insulin

Efects of Deleting A19 Tyrosine Form Insulin

Characteristic, Activity and Conformational Studies of [A6-Ser, A11-Ser]-insulin.

Construction of Met-Lys-double-C peptide human proinsulin gene and its expression and characterization

Ph-Dependent Interactions Of Human Islet Amyloid Polypeptide Segments With Insulin Studied By Replica Exchange Molecular Dynamics Simulations

Characterization of a novel bifunctional mutant of staphylokinase with platelet-targeted thrombolysis and antiplatelet aggregation activities

Mechanisms of allosteric inhibition of Insulin-Regulated Aminopeptidase